Kevin J. Harrington

Research interests

Publications

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00100-1

• Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score

  Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · 2022

• Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.02508

• Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.12.008

• Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02903

• Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30737-3

• The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy

  Frontiers in Oncology · 2020 · https://doi.org/10.3389/fonc.2020.01328

• Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

  Journal for ImmunoTherapy of Cancer · 2020 · https://doi.org/10.1136/jitc-2019-000337

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32591-7

• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0662-5

• The transformation of radiation oncology using real-time magnetic resonance guidance: A review

  European Journal of Cancer · 2019 · https://doi.org/10.1016/j.ejca.2019.07.021

• Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31999-8

• Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

  Cancer Cell · 2018 · https://doi.org/10.1016/j.ccell.2018.02.010

• Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31999-8

• Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

  Oral Oncology · 2018 · https://doi.org/10.1016/j.oraloncology.2018.04.008

• KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy424.045

• Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30421-7

• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602252

Current projects

No projects listed.